OJST  Vol.2 No.3 , September 2012
Metastatic sarcomatoid renal cell carcinoma to the mandible treated with Sorafenib
Abstract: A case of metastatic sarcomatoid renal cell carcinoma to the mandible treated with Sorafenib is reported. A 76-year-old man consulted us for hyposthesia of the right lower lip. Panorama X-ray film showed a ra-diolucent lesion in the right mandibular body. A diagnosis of metastatic tumor to the mandible from the left kidney was made after evaluation by computed tomography and positron emission tomography, which also revealed multiple bone metastases. After radiotherapy for mandibular and thoracic lesions, nephrectomy was performed. Histological diagnosis was sarcomatoid renal cell carcinoma. Interferon therapy was performed but was not effective; therefore, a molecular targeted drug, Sorafenib, was administered. Sorafenib effectively inhibited the growth of oral and other metastatic lesions for 10 months. Quality of life was relatively well maintained with tolerable adverse effects. The patient survived for as long as 2 years after appearance of the first symptom.
Cite this paper: Murakami, K. , Yamamoto, K. , Aoki, K. , Fukumoto, I. , Sugiura, T. and Kirita, T. (2012) Metastatic sarcomatoid renal cell carcinoma to the mandible treated with Sorafenib. Open Journal of Stomatology, 2, 222-227. doi: 10.4236/ojst.2012.23039.

[1]   Oscar, M.R., Raul, G.G., Jesus, M.A., et al. (2009) Metastasis of renal clear-cell carcinoma to the oral mucosa, an atypical location. Medicina Oral, Patologia Oral y Cirugia Bucal, 14, 601-604.

[2]   Pritchyk, K.M., Schiff, B.A., Newkirk, K.A., et al. (2002) Metastatic renal carcinoma to the head and neck. The La- ryngoscope, 112, 1598-1602. doi:10.1097/00005537-200209000-00012

[3]   Montie, J.E., Stewart, B.H., Straffon, R.A., et al. (1977) The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. The Journal of Urology, 117, 272-275.

[4]   Tomera, K.M., Farrow, G.M. and Lieber, M.M. (1983) Sarcomatoid renal cell carcinoma. The Journal of Urology, 130, 657-659.

[5]   Bertoni, F., Ferri, C., Benati, A., et al. (1987) Sarcomatoid renal cell carcinoma of kidney. The Journal of Urology, 137, 25-28.

[6]   Ro, J.Y., Ayala, A.G., Sella, A., et al. (1987) Sarcoma- toid renal cell carcinoma, clinicopathologic. A study of 42 cases. Cancer, 59, 516-526. doi:10.1002/1097-0142(19870201)59:3<516::AID-CNCR2820590327>3.0.CO;2-W

[7]   Shuch, B., Riggs, S.B., LaRochelle, J.C., et al. (2008) Neoadjuvant targeted therapy and advanced kidney cancer: Observations and implications for a new treatment paradigm. BJU International, 102, 692-696. doi:10.1111/j.1464-410X.2008.07660.x

[8]   Hirshberg, A., Leibovich, P. and Buchner, A. (1993) Me- tastasis to the oral mucosa: Analysis of 157 cases. Journal of Oral Pathology & Medicine, 22, 385-390. doi:10.1111/j.1600-0714.1993.tb00128.x

[9]   Fukuda, M., Miyata, M., Okabe, K., et al. (2002) A case series of 9 tumors metastatic to the oral and maxillofacial region. Journal of Oral and Maxillofacial Surgery, 60, 942-944. doi:10.1053/joms.2002.33868

[10]   Meyer, I. and Shklar, G. (1965) Malignant tumors metastatic to mouth and jaws. Oral Surgery, Oral Medicine, Oral Pathology, 20, 350-362. doi:10.1016/0030-4220(65)90167-2

[11]   Astacio, J.N. and Alfano, C. (1969) Oral mucosa metastasis from gastric adenocarcinoma. Oral Surgery, Oral Medicine, Oral Pathology, 28, 859-861. doi:10.1016/0030-4220(69)90339-9

[12]   Nishmura, Y., Yakata, H., Kawasaki, T., et al. (1982) Metastatic tumors of the mouth and jaws: A review of the Japanese literature. Journal of Maxillofacial Surgery, 4, 253-258.

[13]   Zachriades, N. (1980) Neoplasms metastatic to the mouth, jaw and surrounding tissues. Journal of Cranio-Maxillofacial Surgery, 17, 283-290. doi:10.1016/S1010-5182(89)80098-8

[14]   Zohar, Y., Ben-Tovim, R., Gal, R., et al. (1985) Metastatic carcinoma of oral soft tissue. Head & Neck Surgery, 7, 484-486. doi:10.1002/hed.2890070609

[15]   Roser, S.M., Nicholas, T.R. and Hirose, F.M. (1976) Me- tastatic chondrosarcoma to the maxilla: Review of the lit- erature and report of case. Journal of oral surgery, 34, 1012-1015.

[16]   Glaser, C., Lang, S., Pruckmayer, M., et al. (1997) Clini- cal manifestations and diagnostic approach to metastatic cancer of the mandible. International Journal of Oral and Maxillofacial Surgery, 26, 365-368. doi:10.1016/S0901-5027(97)80798-9

[17]   NCCN Clinical Practice Guidelines in Oncology (2010) Kidney Cancer.

[18]   Wilhelm, S.M., Carter, C., Tang, L., et al. (2004) Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research, 64, 7099-7109. doi:10.1158/0008-5472.CAN-04-1443

[19]   Bukowski, R.M., Eisen, T., Szczylik, C., et al. (2007) Final results of the randomized phase trial of Sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. Journal of Clinical Oncology, 25, 5023.

[20]   Motzer, R.J., Rini, B.I., Bukowski, R.M., et al. (2006) Activity of SU 11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 24, 16-24. doi:10.1200/JCO.2005.02.2574

[21]   Lacouture, M.E., Reilly, L.M., Gerami, P., et al. (2008) Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Annals of Oncology, 19, 1955-1961. doi:10.1093/annonc/mdn389

[22]   Nagengast, W.B., Lub-de Hooge, M.N., Oosting, S.F., et al. (2010) VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Research, 71, 143-153. doi:10.1158/0008-5472.CAN-10-1088

[23]   Llovet, J.M., Ricci, S., Mazzaferro, V., et al. (2008) Soraf-enib in advanced hepatocellular carcinoma. The New England Journal of Medicine, 359, 378-390. doi:10.1056/NEJMoa0708857